- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05778162
RISC Panel Remnant Sample Collection
Evaluation of the Usability and Clinical Utility of the Synovasure® RISC Panel
The primary objective of this study is to evaluate the usability and clinical utility of the Synovasure® RISC™ Panel.
The secondary objective of this study is to create a repository of well-characterized synovial fluid samples from patients with knee pain and/or inflammation to be used for future research.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Synovasure® RISC Panel™ constitutes a single source of pre-operative biomarker testing with high predictive value for the diagnosis of single or multiple arthritis conditions, that may correspond to a relative level of inflammation and post-operative complication and infection risk in patients with knee pain and/or inflammation.
The aim of this clinical performance post-market clinical follow-up (PMCF) study is to evaluate the usability and clinical utility of the Synovasure® RISC Panel™ using comparative analyses between the suspected diagnosis, patient demographics, conditions, symptoms, medical history and the Synovasure® RISC Panel™ results. The secondary objective of this study is to create a repository of well-characterized synovial fluid samples from patients with knee pain and/or inflammation to be used for future research.
Investigators will perform arthrocentesis as part of the patient's standard of care. Remnant samples will be transferred in the tubes included with the Synovasure® Arthritis Specimen Transportation kit, in accordance with instructions and the requisition form. Additional case report forms (CRFs) to collect demographic, and clinical data beyond what is included in the requisition form and the Panel results accession identification (ID) will be provided. Sample collection and shipment to CD Laboratories (CDL) may be limited to Monday-Wednesday. A maximum of three samples per transportation kit will be shipped as soon as the samples are collected. CDL will perform RISC™ Panel testing and identifiable results will be provided to enable the centers to pair the test results with clinical outcome data. De-identified leftover remnant samples will be frozen and all data, including any available clinical outcome data, will also be entered into a de-identified database of results and made accessible to all participating investigators for research purposes.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Elena Gardini
- Phone Number: +1(206)475-2093
- Email: elena.gardini@zimmerbiomet.com
Study Contact Backup
- Name: Ann Blanton
- Phone Number: +1 (574) 253-5556
- Email: ann.blanton@zimmerbiomet.com
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Recruiting
- Rothman Orthopaedic Institute
-
Contact:
- Thema Nicholson
- Phone Number: 800-321-9999
- Email: thema.nicholson@rothmanortho.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with knee pain and/or inflammation and planned arthrocentesis
Exclusion Criteria:
- Patient is unwilling or unable to give oral consent
- Patient has any condition that would, in the judgment of the Investigator, place the patient at undue risk or interfere with the study
- Patient is a vulnerable subject (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, anticipated to be non-compliant)
- Patient had an arthrocentesis of the index joint less than 2 weeks from the planned arthrocentesis
- Insufficient synovial fluid sample of < 1.5 mL
- Patient age < 18 or > 89
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of agreement
Time Frame: 2 years
|
This study is intended to characterize the performance of the Synovasure® RISC™ Panel in a real-world environment.
The primary endpoint of this study is the rate of agreement (positive and negative) of the test result with the suspected diagnosis.
The suspected diagnosis of the index knee will be collected prior to the Synovasure® RISC™ Panel analyses to be subsequently matched to the Synovasure® RISC™ Panel results.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relationship between patient characteristics and panel results
Time Frame: 2 years
|
The secondary endpoint will consist of an exploration of potential correlations between the subject characteristics and results of the RISC panel diagnostics.
Analysis of Variance (ANOVA) will be used to test for associations, while chi-square tests or Fisher's exact tests will be used for categorical variables.
Logistic regressions may be performed to examine diagnostic accuracy based on variables identified to be significant predictors (p-value ≤ 0.05) from the univariate analyses.
|
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Krista Toler, Zimmer Biomet
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DTU2022-21DI
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arthritis, Inflammatory
-
Sunnybrook Health Sciences CentreUniversity Health Network, Toronto; University of TorontoCompleted
-
Assiut UniversityNot yet recruitingSubtalar Osteoarthritis Secondary to Inflammatory Arthritis
-
Sunnybrook Health Sciences CentreCanadian Initiative for Outcomes in Rheumatology CareTerminated
-
University of LorraineUnknownInflammatory Arthritis
-
University of SaskatchewanCanadian Initiative for Outcomes in Rheumatology CareCompletedInflammatory ArthritisCanada
-
Mayo ClinicGE HealthcareNot yet recruitingInflammatory ArthritisUnited States
-
Sunnybrook Health Sciences CentreUniversity of British ColumbiaActive, not recruiting
-
McMaster UniversityUnknown
-
Guy's and St Thomas' NHS Foundation TrustNot yet recruitingInflammatory Arthritis
-
University of LeedsRecruitingInflammatory ArthritisUnited Kingdom
Clinical Trials on Synovasure® RISC™ Panel
-
UMC UtrechtZimmer BiometEnrolling by invitationPeriprosthetic Joint Infection | PJINetherlands, Spain, Germany, Portugal, Slovenia, Switzerland
-
BioFire Diagnostics, LLCNational Institute of Allergy and Infectious Diseases (NIAID)CompletedInfectious GastroenteritisUnited States
-
Abbott Rapid DxCompletedCOVID-19 | Influenza A | Influenza BUnited States
-
Abbott Rapid DxCompletedCOVID-19 | Influenza A | Influenza Type BUnited States
-
Abbott Rapid DxRecruitingCOVID-19 | Influenza A | Influenza Type BUnited States
-
Centre Leon BerardCompleted
-
Abbott Rapid DxCompletedCOVID-19 | Influenza A | Influenza Type BUnited States
-
Instituto Nacional de Ciencias Medicas y Nutricion...CompletedPancreatic Cancer | Pancreatic AdenocarcinomaMexico
-
Andrew MeltzerBioMérieuxCompletedAcute Respiratory Infection | Viral Infection | Upper Resp Tract InfectionUnited States